Cone optogenetics for vision restoration
Location: Switzerland, Basel-City, Basel
Total raised: $94.27M
Investors 2
| Date | Name | Website |
| 17.05.2025 | ARCH Ventu... | archventur... |
| 11.01.2025 | F-Prime Ca... | fprimecapi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.01.2025 | Series A | $94.27M | - |
Mentions in press and media 6
| Date | Title | Description |
| 02.07.2026 | Biotech and Food companies strengthen management teams on the business side | Basel-based pharma company Idorsia has appointed Roland Wandeler as CEO, effective October 1, 2026. He will succeed Jean-Paul Clozel, who has been serving as ad interim CEO since March 2026 and will continue as Chairman of the Board of Dir... |
| 07.03.2025 | The future of Swiss tech: 10 promising startups you should keep an eye on in 2025! | Switzerland has long been a leader in innovation, research, and cutting-edge technology. Known for its strong academic institutions, stable economy, and business-friendly environment, the country has established itself as a powerhouse in de... |
| 15.01.2025 | RhyGaze raises CHF 86 million to advance gene therapy for retinal diseases | RhyGaze was founded on intellectual property exclusively licensed to the company by the Institute of Molecular and Clinical Ophthalmology Basel (IOB), a scientific institute led by Director Botond Roska, who is a scientific co-founder of R... |
| 13.01.2025 | RhyGaze: $86 Million (Series A) Raised To Develop Gene Therapies For Retinal Diseases | RhyGaze, a biotechnology company based in Basel, Switzerland, and Philadelphia, PA, announced that it has raised a Series A funding round of $86 million. The funding round was led by GV (Google Ventures), alongside Arch Venture Partners, F-... |
| 13.01.2025 | RhyGaze Closes USD 86M Series A Funding | RhyGaze, a Basel, Switzerland- and Philadelphia, PA-based biotechnology company developing gene therapies for retinal diseases, raised USD 86M in Series A funding. The round was led by GV (Google Ventures), alongside Arch Venture Partners, ... |
| - | Rhygaze | “RhyGaze is at the forefront of developing a novel first-in-class gene therapy aimed at improving vision in patients suffering from retinal diseases.” |